ArticleAmerican journal of preventive cardiology2026
Hematologic biomarkers of aging (HemeAge) and cardiovascular risk: a machine learning analysis in two cohorts.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronological age inadequately reflects aging variability and cardiovascular risk. Biological age derived from routine complete blood count (CBC) parameters may provide a more actionable marker. Objective: To develop a machine learning model of biological age using CBC data (HemeAge) and evaluate associations with mortality and major adverse cardiovascular events (MACE) in two large cohorts. Methods: An XGBoost model was trained on 53,355 NHANES participants (1999-2010) to predict chronological age from CBC parameters. The model was applied to 109,844 Houston Methodist CVD Registry patients, generating "delta age" (predicted minus chronological age). Patients were classified as Resilient (delta < -10), Proportionate (-10 ≤ delta ≤ 10), or Accelerated (delta > 10). Cox models assessed mortality and MACE risk, adjusting for demographics and clinical factors. Results: Red cell distribution width, mean cell volume, and neutrophil count were key age predictors. Accelerated aging associated with increased mortality risk (HR 3.05, 95% CI 2.41-3.85) and MACE (HR 1.37, 95% CI 1.24-1.51) versus proportionate aging. Resilient aging conferred reduced risk for mortality (HR 0.59, 95% CI 0.52-0.68) and MACE (HR 0.76, 95% CI 0.72-0.81). Associations were strongest in midlife (ages 40-80) and for death and heart failure outcomes and persisted across age-stratified and continuous models. Conclusions: HemeAge independently predicts mortality and cardiovascular risk beyond chronological age. These accessible hematologic markers may enhance risk stratification and inform targeted prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.